Cargando…

661. In vitro Activity of Omadacycline and Comparator Antibiotics against Clostridioides difficile

BACKGROUND: Omadacycline was approved for the treatment of community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in 2018. Previous studies demonstrate that omadacycline has in vitro activity against Clostridioides difficile. We determined the i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skinner, Andrew M, Petrella, Laurica A, Cheknis, Adam K, Johnson, Stuart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752168/ http://dx.doi.org/10.1093/ofid/ofac492.713

Ejemplares similares

386. Clostridioides difficile PCR Cycle Threshold to Determine Toxin Positivity Status
por: Crone, Andrew S, et al.
Publicado: (2022)

595. Recovery of Clostridioides difficile Isolates from Cary-Blair Transport Medium Compared to No Transport Medium
por: Skinner, Andrew M, et al.
Publicado: (2023)

In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile
por: Begum, Khurshida, et al.
Publicado: (2020)

In Vitro Activity of Omadacycline and Five Comparators against Contemporary Ribotypes of Clostridioides difficile in Stockholm, Sweden
por: Camporeale, Angela, et al.
Publicado: (2021)

277. A Functional OMICs Evaluation of Omadacycline to Understand Anti-Clostridioides difficile Protective Effects
por: Jo, Jinhee, et al.
Publicado: (2023)

403. Strain Epidemiology of Clostridioides difficile across Three Geographically Distinct Medical Centers in Chicago
por: Kim, Do Young, et al.
Publicado: (2022)

1037. Efficacy of Germinants and Omadacycline for Preventing Clostridioides difficile Relapse in a Murine Model
por: Budi, Noah, et al.
Publicado: (2021)

400. Rehospitalization of Patients for Recurrent Clostridioides difficile Infection
por: Drwiega, Emily, et al.
Publicado: (2022)

Unique Clindamycin-Resistant Clostridioides difficile Strain Related to Fluoroquinolone-Resistant Epidemic BI/RT027 Strain
por: Skinner, Andrew M., et al.
Publicado: (2020)

Omadacycline and Clostridioides difficile: A Systematic Review of Preclinical and Clinical Evidence
por: Garey, Kevin W., et al.
Publicado: (2022)

Effect of the COVID-19 Pandemic on Rates and Epidemiology of Clostridioides difficile Infection in One VA Hospital
por: Wright, Lorinda M., et al.
Publicado: (2023)

Absence of toxin gene transfer from Clostridioides difficile strain 630Δerm to nontoxigenic C. difficile strain NTCD-M3r in filter mating experiments
por: Sambol, Susan P., et al.
Publicado: (2022)

Efficacy of Omadacycline or Vancomycin Combined With Germinants for Preventing Clostridioides difficile Relapse in a Murine Model
por: Budi, Noah D, et al.
Publicado: (2022)

1208. Omadacycline In Vitro Activity Against Bacillus Anthracis
por: Serio, Alisa W, et al.
Publicado: (2021)

381. Antibiotic Spectrum Index and Risk of Clostridioides difficile Infection
por: Ray, Michael J, et al.
Publicado: (2022)

797. Management of Patients with Multiple Clostridioides difficile Infection Recurrences using a Tapered-Pulsed Fidaxomicin Strategy
por: Tan, Xing, et al.
Publicado: (2020)

2432. Durability Against Antibiotics After Response to Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Saha, Srishti, et al.
Publicado: (2019)

2385. Evaluating the Antibiotic Risk for Clostridioides difficile Infection (CDI): Comparing Piperacillin/Tazobactam to Cefepime and Ceftazidime
por: Rathod, Shardul, et al.
Publicado: (2019)

In Vitro Activities of Omadacycline and Comparators against Anaerobic Bacteria
por: Stapert, Laure, et al.
Publicado: (2018)

2577. Comparing Omadacycline with Existing Antibiotics in the treatment of Acute Bacterial Infections: A Systematic Review
por: Fabara, Stephanie P, et al.
Publicado: (2023)

801. Patients with Clostridioides difficile Infection Following Dental Antibiotic Prescription
por: Wilson, Geneva M, et al.
Publicado: (2020)

688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile
por: Basseres, Eugenie, et al.
Publicado: (2019)

1374. Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic
por: Opal, Steven, et al.
Publicado: (2018)

1492. Targeted Substitution of Omadacycline in Place of Standard of Care for CABP Treatment is Associated with a Risk Reduction of Clostridioides difficile Infection and Financial Cost Savings in the Acute Care Setting
por: Rodriguez, Mauricio, et al.
Publicado: (2020)

2388. High-risk antibiotics associated with Clostridioides difficile infection: a national, multicenter analysis
por: Young, Eric H, et al.
Publicado: (2019)

Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
por: Lodise, Thomas P., et al.
Publicado: (2021)

1586. A Comparative Analysis of In Vitro Susceptibilities of Vancomycin-Resistant Enterococci Against Doxycycline, Minocycline, Tigecycline, Eravacycline and Omadacycline
por: Chua, Mary Francine P, et al.
Publicado: (2020)

236. Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities
por: Tillotson, Glenn S, et al.
Publicado: (2022)

2518. Lead optimization on 26-membered thiopeptide antibiotics and identification of pre-clinical candidates against Clostridioides difficile and Staphylococcus aureus for impetigo
por: Hwang, Hee-Jong, et al.
Publicado: (2023)

221. Assessment and Proposed Revision of Clinical Trial Clostridioides difficile Infection Clinical Response and Outcomes Definitions
por: Gonzales-Luna, Anne J, et al.
Publicado: (2022)

2413. Assessment of compliance with Clostridioides difficile prophylaxis guideline and its efficacy on secondary prophylaxis and reducing hospital-onset Clostridioides difficile infections.
por: Vyas, Nikunj M, et al.
Publicado: (2019)

1985. Impact of Suppressing Ciprofloxacin Susceptibility Results on Antibiotic Utilization and Hospital-acquired Clostridioides difficile Infection
por: White, Bryan P, et al.
Publicado: (2019)

657. Impact of Oral Vancomycin Duration on Clostridioides difficile Recurrence in Patients Requiring Concurrent Systemic Antibiotics
por: Marsh, Kassandra, et al.
Publicado: (2023)

680. Comparison of Extended Duration Vancomycin Regimens for Clostridioides difficile Infection in Patients on Prolonged Antibiotic Courses
por: Garzia, Christopher, et al.
Publicado: (2023)

1188. Efficacy of Copper Impregnated Self-Sanitizing Surface Against Clostridioides difficile Spores
por: Ashby, Landon, et al.
Publicado: (2022)

In Vitro Activity of Omadacycline and Comparator Compounds Against Gram-positive Isolates Collected in the USA During 2016 as Part of a Global Surveillance Program
por: Huband, Michael D, et al.
Publicado: (2017)

Frontiers in antibiotic alternatives for Clostridioides difficile infection
por: Phanchana, Matthew, et al.
Publicado: (2021)

471. Prevalence and Characteristics of Clostridioides difficile Infection in Bangladesh
por: Sofjan, Amelia K, et al.
Publicado: (2018)

2387. Learning the Influence of Individual Clostridioides difficile Infections
por: Mu, Emily, et al.
Publicado: (2019)

2347. Impact of Multidisciplinary Review of Clostridioides difficile Testing
por: Foreman, Jena, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_reennfbrlnir77s3me8o89vhac